Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Johns Hopkins University, Baltimore, MD, USA.
Clinical Research Branch, National Institute on Aging, Baltimore, MD, USA.
Lancet Diabetes Endocrinol. 2014 Oct;2(10):819-29. doi: 10.1016/S2213-8587(14)70034-8. Epub 2014 Mar 6.
The term sarcopenia refers to the loss of muscle mass that occurs with ageing. On the basis of study results showing that muscle mass is only moderately related to functional outcomes, international working groups have proposed that loss of muscle strength or physical function should also be included in the definition. Irrespective of how sarcopenia is defined, both low muscle mass and poor muscle strength are clearly highly prevalent and important risk factors for disability and potentially mortality in individuals as they age. Many chronic diseases, in addition to ageing, could also accelerate decrease of muscle mass and strength, and this effect could be a main underlying mechanism by which chronic diseases cause physical disability. In this Review, we address both age-related and disease-related muscle loss, with a focus on diabetes and obesity but including other disease states, and potential common mechanisms and treatments. Development of treatments for age-related and disease-related muscle loss might improve active life expectancy in older people, and lead to substantial health-care savings and improved quality of life.
肌肉减少症是指随着年龄增长而发生的肌肉质量损失。基于研究结果表明肌肉质量与功能结果仅有中度相关性,国际工作组提出肌肉力量或身体功能的丧失也应包含在定义中。无论如何定义肌肉减少症,肌肉质量低和肌肉力量差在个体衰老时显然是高度普遍且重要的残疾和潜在死亡风险因素。除了衰老之外,许多慢性疾病也可能加速肌肉质量和力量的下降,这种影响可能是慢性疾病导致身体残疾的主要潜在机制。在这篇综述中,我们既关注与年龄相关的肌肉减少,也关注与疾病相关的肌肉减少,重点关注糖尿病和肥胖症,但也包括其他疾病状态,以及潜在的共同机制和治疗方法。针对与年龄相关和与疾病相关的肌肉减少症的治疗方法的发展可能会提高老年人的活跃预期寿命,并带来大量的医疗保健节省和提高生活质量。